HC Wainwright Equities Analysts Decrease Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPRFree Report) – Investment analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Esperion Therapeutics in a research note issued on Monday, March 25th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of $2.50 per share for the year, down from their previous forecast of $4.13. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2027 earnings at $3.40 EPS and FY2028 earnings at $6.41 EPS.

Other equities research analysts also recently issued research reports about the company. Bank of America downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Esperion Therapeutics in a report on Monday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and an average target price of $9.33.

Get Our Latest Report on ESPR

Esperion Therapeutics Stock Up 3.1 %

Shares of ESPR opened at $2.70 on Wednesday. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.34. The stock’s fifty day simple moving average is $2.37 and its 200-day simple moving average is $1.79.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the prior year, the firm earned ($0.76) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ESPR. Wasatch Advisors LP boosted its position in Esperion Therapeutics by 95.0% during the first quarter. Wasatch Advisors LP now owns 13,354,186 shares of the biopharmaceutical company’s stock valued at $21,233,000 after purchasing an additional 6,505,808 shares during the last quarter. Armistice Capital LLC acquired a new position in Esperion Therapeutics during the first quarter valued at approximately $5,850,000. Jacobs Levy Equity Management Inc. lifted its position in shares of Esperion Therapeutics by 429.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,264,359 shares of the biopharmaceutical company’s stock valued at $2,219,000 after buying an additional 1,836,567 shares during the last quarter. Wasatch Advisors Inc. lifted its position in shares of Esperion Therapeutics by 27.6% in the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company’s stock valued at $37,804,000 after buying an additional 1,761,117 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company’s stock valued at $17,212,000 after buying an additional 1,457,952 shares during the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Read More

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.